SV

Street Verdict

Analyst Scorecard

LALPATHLAB · NSE

Dr. Lal Path Labs Ltd.

₹2,006

+2.18% (+₹42.8)

Prev. close

₹1,963.2

Volume

2,64,951

Delivery %

52.5%

As of

20 Nov 2026

Price history

₹2,006+₹104.6 (+5.50%) · 3M
18 Aug 2026 → 20 Nov 2026
1,8501,9001,9502,00018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Dr. Lal Path Labs Ltd.

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

Details

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Mr. Shankha Banerjee

Headquarters

Gurugram

Employees

5,206

Key stats

Market cap

₹33,933.74 Cr

P/E ratio (TTM)

62.7

Dividend yield

1.04%

EPS (TTM)

₹32.39

Beta (1Y · daily vs NIFTY 50)

0.38

Beta (5Y · monthly vs NIFTY 50)

0.89

Shares float

7.58 Cr

EPS · quarter ended Jun 2026

₹10.13

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹0%5%10%15%20%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

010203040₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0246₹-100%0%100%200%05 Mar 2018 Nov 2009 Feb 2120 Jul 2118 Aug 2122 Jun 2205 Aug 2211 Aug 2313 Feb 2410 Jun 2420 Aug 2405 Nov 2405 Feb 2506 Jun 2506 Aug 2507 Nov 2505 Feb 2625 Jun 2630 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-200%0%200%400%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-500 Cr0 Cr500 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,581.30 Cr₹2,087.40 Cr₹2,016.90 Cr₹2,226.60 Cr₹2,461.40 Cr₹2,762.90 Cr
EBITDA
₹487.60 Cr₹613.20 Cr₹531.60 Cr₹678.50 Cr₹788.90 Cr₹853.70 Cr
₹291.60 Cr₹344.80 Cr₹238.90 Cr₹357.70 Cr₹487.10 Cr₹504.80 Cr
Diluted EPS
₹17.63₹20.79₹14.37₹21.49₹29.2₹30.2

Net income for Mar 2021 could not be checked against the company's own annual report: this page shows ₹291.60 Cr while the annual report gives ₹296.50 Cr (1.7% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹227.60 Cr) is left blank here too, rather than shown from only one of the two sources.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,661.00 Cr₹2,343.00 Cr₹2,383.00 Cr₹2,454.00 Cr₹2,713.00 Cr₹3,140.00 Cr
—₹532.57 Cr₹419.50 Cr₹246.93 Cr₹157.43 Cr₹198.99 Cr
Stockholders' equity
₹1,245.00 Cr₹1,501.00 Cr₹1,666.00 Cr₹1,849.00 Cr₹2,173.00 Cr₹2,509.00 Cr

Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹398.00 Cr₹447.00 Cr₹456.00 Cr₹535.00 Cr₹569.00 Cr₹636.00 Cr
Investing cash flow
₹-212.00 Cr₹-449.20 Cr₹-287.30 Cr₹-24.30 Cr₹-303.10 Cr₹-421.90 Cr
₹-139.00 Cr₹136.00 Cr₹-283.00 Cr₹-414.00 Cr₹-334.00 Cr₹-264.00 Cr
Capital expenditure
₹-60.00 Cr₹-476.00 Cr₹-45.00 Cr₹-57.00 Cr₹-54.00 Cr₹-173.00 Cr
End cash position
₹244.30 Cr₹378.20 Cr₹263.70 Cr₹360.90 Cr₹292.60 Cr₹242.80 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25–Dec 25(2Q)Mar 26Jun 26
Promoter55.23%55.23%55.23%55.05%55.05%55.05%55.03%55.01%54.61%54.60%54.60%54.60%53.92%53.91%53.91%53.79%53.21%53.21%53.21%53.19%
Public43.97%44.03%44.07%44.35%44.38%44.39%44.45%44.55%44.98%45.03%45.08%45.10%45.75%45.81%45.83%45.82%46.42%46.44%46.44%46.43%
Employee trusts0.80%0.74%0.70%0.60%0.58%0.56%0.51%0.44%0.41%0.37%0.32%0.30%0.33%0.28%0.27%0.39%0.37%0.35%0.34%0.38%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Dr. Lal Path Labs Ltd.₹32,199.77 Cr₹2,029.459.412.8420.1%0.08+12.3%-35.7%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

LALPATHLAB

Dr. Lal Path Labs Q2 profit soars 28% YoY, EBITDA margin expands; dividend of ₹5/share declared

Upstox · 18 days ago

LALPATHLAB

Dr. Lal Path Labs (LALPATHLAB.NS) Eases 0.93% to ₹1934.2 as Diagnostics Major Holds Above Key Support - Max Pain Level

siam.in · 2 months ago